RAPID IDENTIFICATION AND ANTIBIOTIC SUSCEPTIBILITY TESTING IN HOURS, NOT DAYS


RAPID IDENTIFICATION AND ANTIBIOTIC SUSCEPTIBILITY TESTING IN HOURS, NOT DAYS


Learn about our technology from our Scientific Founder and Chief Executive Officer, James McNamara, PhD

Speed is Life1

Early treatment, enabled by rapid diagnosis and determination of appropriate antibiotic therapy, has been shown to improve patient outcomes, save lives, and reduce costs.

Rapid Pathogen Identification

Nuclease Probe Technologies provides rapid pathogen identification directly from the blood of patients suspected of having bloodstream infections and, our goal is to help to determine which antibiotic can be most effective in treating the patient—a process called antibiotic susceptibility testing or AST. AST typically takes days to provide results that inform physician of the best treatment for their patient. NPT plans to reduce that time to hours, eliminating unnecessary delays in treatment.

-

Speed is Life1

Early treatment has been shown to improve patient outcomes, save lives, and reduce costs.

Rapid Pathogen Identification

Nuclease Probe Technologies provides rapid pathogen identification directly from the blood of patients suspected of having bloodstream infections and, our goal is to help to determine which antibiotic can be most effective in treating the patient—a process called antibiotic susceptibility testing or AST. AST typically takes days to provide results that inform physician of the best treatment for their patient. NPT plans to reduce that time to hours, eliminating unnecessary delays in treatment.


The Science

NPT has pioneered a new field of diagnostics, called signal amplifying biomarkers, that provide unparalleled sensitivity and specificity. Signal amplifying biomarkers are simple in concept. Signal amplification only occurs if the biomarker is present in the specimen being tested. This approach reduces signal to noise interference and other artifacts created by current methods such as polymerase chain reaction (PCR), or traditional immunoassays.

biosenor model, NPT Rapid Testing

Specificity

Nuclease Probe Technologies harnesses a group of signal amplifying biomarkers called nucleases to drive our core NucAP™ assay. Nucleases are enzymatic proteins essential for life and expressed by all living things including bacteria. NucAP™ is a simple blood test which uses nucleases secreted by pathogenic bacteria like Staphylococcus aureus, for the specific detection of Staphylococcus aureus bacteremia (SAB) directly from a sample of the patient’s blood. The NucAP™ test has been compared to the gold standard—blood culture and determined to be 97% specific for SAB. SAB is a potentially deadly bloodstream infection caused by bacteria.


Sensitivity

NPT’s NucAP™ test was found to be 100% sensitive when compared to blood culture in detecting potentially deadly Staphylococcus aureus bacteria. Blood culture is the gold standard laboratory diagnostic test. In further laboratory studies NPT has demonstrated sensitive detection of bacteria to less than 0.01 CFU/mL. This sensitivity is unmatched in the industry.

Specificity Bar Graph

The Process

The outstanding sensitivity and specificity of the NucAP™ test allows NPT to determine the presence of bacteria in the blood of patients suspected of having critical bloodstream infections within hours without the need to first culture the blood. Patient specimens that are positively identified with pathogenic bacteria can be further analyzed to determine the most appropriate antibiotic therapy. NPT’s planned approach is designed to mirror classic laboratory approaches by incubating the specimen in the presence of antibiotics to determine which will be the most effective therapy to treat the patient. The result will be pathogen identification and optimal treatment options in hours not days it often takes for typical culture-based methods to determine pathogen ID and antibiotic susceptibility.

Projected Work-flow

Technical Papers

Building a Rich Pipeline


Building a Rich Pipeline


Bloodstream Detection of Pathogens

We are developing a panel of tests targeting the deadliest bloodstream pathogens

Learn more

Pathogen Detection from Urine

Our technology can be used to identify infectious diseases like urinary tract infections

Learn more

Circulating Cancer Detection from Blood

Identification nuclease activity from circulating tumor cells

Learn more

About NPT


Nuclease Probe Technologies was founded to address one of the most basic issues in diagnostics—the sensitive detection of disease with the premise that early detection means physicians can make informed treatment decisions faster and achieve better outcomes for the patient and the healthcare system.

Leadership

Scientific Founder and Chief Executive Officer — James McNamara, Ph.D.


James McNamara, PhD

James is an Associate Professor of Internal Medicine - Hematology, Oncology and Blood and Marrow Transplantation at the University of Iowa and an author of twenty-four peer-reviewed scientific articles, including the formative, high impact publication on Staphylococcus aureus micrococcal nuclease which appeared in Nature Medicine (2014). He is an inventor on three U.S. patents, including the key ‘949 patent, and has two patents pending. James has generated over $2.3 M in dedicated grant funding for the core Nuclease-Activated Probe (NucAP™) technology. James successfully negotiated the license for his invention from the University of Iowa Research Foundation (UIRF). James founded Nuclease Probe Technologies, NPT, in 2014 based on his patented work with bacterial nucleases and recruited a team of subject matter experts to provide advisory services. NPT is focused on developing rapid diagnostic assays to detect disease-associated nuclease activities. The early and sensitive detection of infectious diseases has been shown to improve patient outcomes and reduce costs to the healthcare system.

Advisor

Senior Executive Advisor — Philippe Nore


Philippe Nore

Philippe is an experienced Startup CEO in the Life Sciences industry with a passion for driving the adoption of new products and technologies. Prior to NPT, he co-founded and led as CEO for several years MiNDERA, a MedTech company developing Next-Generation Skin Diagnostics & Analytics. Prior to MiNDERA Philippe was Senior International Business Leader at Roche Diagnostics where he held global P & L responsibility and launched several FDA-approved products. Philippe has held prior business consulting roles in the life sciences industry with Bain & Company a global management consulting firm, and for LEK Consulting, a world renown management and strategy consulting firm. Philippe is a proven general manager and business development expert in the Life Sciences industry with extensive US and international experience. Philippe has a demonstrated track record of developing and launching new businesses and a passion for driving the adoption of new products and technologies. Philippe holds a MSc. in chemistry from ESPCI (Paris) and an MBA from the Wharton School where he graduated as a Palmer Scholar.

Join our Team

Nuclease Probe Technologies is building a new class of diagnostic tools harnessing the enzymatic potential of proteins to solve major problems in healthcare such as developing a test for the early identification of pathogens, which can cause a life-threatening condition called sepsis. Our approach is truly unique and we are looking for passionate, driven, individuals who want to join with us and help us create these new tools. If this sounds like you, please check out our open positions, and drop us a note; we’d love to hear from hear from you.

Open Position(s)


Seeking Assay Development Scientist I/II - Molecular Biology

Apply

The key responsibility will be, working with a team, to develop a new easy-to-use, ultrasensitive, fast, diagnostic platform for infectious disease diagnostics with an initial focus on bloodstream pathogens. The applicants should enjoy the environment and opportunities in a start-up where resourceful, hands-on, proactive, and multitasking are a must.....Learn More

Job Location: Lowell, MA
 

Nuclease Probe Technologies, Inc. is proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability or any other status protected under federal, state or local law. All employment is decided on the basis of qualifications, merit, and business need.

NPT News


Nuclease Probe Technologies raises $500,000 from Breakout Labs to Support Development of Rapid Antibiotic Susceptibility Testing for Bloodstream Infections

Nuclease Probe Technologies raises $500,000 from Breakout Labs to Support Development of Rapid Antibiotic Susceptibility Testing for Bloodstream Infections

March 5, 2019 08:00 AM Eastern Daylight Time
Lowell, MA—Nuclease Probe Technologies, Inc., a company pioneering a precision medicine approach to matching patients with the most effective antibiotics to treat deadly bloodstream infections, announces the investment by Breakout Labs, a Thiel Foundation fund that backs scientist-entrepreneurs transitioning scientific breakthroughs out of the lab and into the market. Read More...

Contact Us


Nuclease Probe Technologies, Inc.

110 Canal Street, 4th Floor
c/o M2D2
Lowell, MA 01852

For business development or other inquiries please contact bd@nptrapidtesting.com.

Connect with Us on LinkedIn